|
注册号: Registration number: |
ChiCTR2400087231 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-23 11:21:05 |
|
注册时间: Date of Registration: |
2024-07-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于线上问卷的女性月经周期调查和卵巢健康风险评估 |
|
Public title: |
A survey of women's menstrual cycle and ovarian health risk assessment via online questionnaires |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于线上问卷的女性月经周期调查和卵巢健康风险评估 |
|
Scientific title: |
A survey of women's menstrual cycle and ovarian health risk assessment via online questionnaires |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴琰婷 |
研究负责人: |
黄荷凤 |
|
Applicant: |
Wu Yanting |
Study leader: |
Huang Hefeng |
|
申请注册联系人电话: Applicant telephone: |
+86 173 2121 8018 |
研究负责人电话:
Study leader's |
+86 21 6407 0434 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
+86 21 64073421 | |
|
申请注册联系人电子邮件: Applicant E-mail: |
yanting_wu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
huanghefg@sjtu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海黄浦区方斜路 419号 |
研究负责人通讯地址: |
上海黄浦区方斜路 419号 |
|
Applicant address: |
419 Fangxie Road, Huangpu District, Shanghai, China |
Study leader's address: |
419 Fangxie Road, Huangpu District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
200011 |
研究负责人邮政编码: Study leader's postcode: |
200011 |
|
申请人所在单位: |
复旦大学附属妇产科医院 |
||
|
Applicant's institution: |
Obstetrics and Gynecology Hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属妇产科医院 |
||
|
Affiliation of the Leader: |
Obstetrics and Gynecology Hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
妇产科伦审2024-96 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属妇产科医院伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Obstetrics and Gynecology Hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-03 00:00:00 | ||
|
伦理委员会联系人: |
姜桦 |
||
|
Contact Name of the ethic committee: |
Jiang Hua |
||
|
伦理委员会联系地址: |
上海黄浦区方斜路419 号 |
||
|
Contact Address of the ethic committee: |
419 Fangxie Road, Huangpu District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 5351 3815 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属妇产科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Obstetrics and Gynecology Hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海黄浦区方斜路 419 号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
419 Fangxie Road, Huangpu District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
华为终端有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Huawei Device (Shenzhen) Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
卵巢储备功能减退 |
||||||||||||||||||||||
|
Target disease: |
diminished ovarian reserve |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究将通过线上问卷收集华为可穿戴设备女性用户的人口学特征和月经周期、压力、更年期症状等自我报告数据,通过可穿戴设备采集心率、体温、睡眠等生理信息,通过数据模型,分析研究对象的月经周期特点,是否存在卵巢功能减退风险。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study will collect and analyze data such as demographic information, menstrual cycle, stress, menopause symptoms, heart rate, body temperature and sleep via online questionnaire, wearable devices and machine-learning algorithms to determine the menstrual cycle characteristics and the risk of diminished ovarian reserve of the participants. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
患有严重系统性疾病或任何不稳定的疾病或医疗状况,根据医学标准判定可能会危及患者安全性及其对研究要求的依从性。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Severe systemic disease or any unstable disease or medical condition that, according to medical criteria, may jeopardize patient safety and her compliance with the requirements of the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-08-01 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
项目完成半年后,需要原始数据的人员申请并通过项目委员会批准后将通过加密邮件方式传输给申请人员。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data will be transmitted to the applicant through encrypted mail after approval by the project committee. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |